Blog - Page 3104 of 5689

ThursdayJan 03, 2013 2:34 pm

Discovery Laboratories, Inc. (DSCO) Begins Initial Phase of AFECTAIR® Launch

Discovery Laboratories, a specialty biotechnology company dedicated to raising the standard in respiratory critical care, announced today that the launch of its AFECTAIR® airway connector has been initiated. The AFECTAIR® airway connector is designed for infants needing aerosolized medication in neonatal or pediatric intensive care units (NICU and PICU, respectively), and it simplifies medication delivery for those critical care patients who need ventilatory support. This simplification is provided through the innovative process of introducing the medication directly at the patient interface. The initial phase of the launch is the introduction of an AFECTAIR user experience program in leading U.S. critical…

ThursdayJan 03, 2013 2:33 pm

SunLink Health Systems, Inc. (SSY) Completes Sale of Assets of Missouri Hospital

SunLink Health Systems completed the sale of nearly all assets, and the leasehold interest of Dexter Hospital, LLC, to Southeast Health Center of Stoddard County, LLC. Southeast Health Center of Stoddard County is an indirect subsidiary of Southeast Missouri Hospital Association (D/B/A SoutheastHEALTH). The assets included a leased 50-bed acute care hospital and related clinics, equipment, and home health services in Dexter, MO. The sale of the assets and leasehold interest was for approximately $9.8 million, less estimated sale expenses and taxes. It is expected to result in net proceeds of approximately $7.4 million and an after tax gain of…

ThursdayJan 03, 2013 10:54 am

TNI BioTech, Inc. (TNIB) Scheduled to Present at 6th Annual OneMedForum Conference

TNI BioTech, a biotech company utilizing patented immunotherapy to activate and mobilize the body’s immune system to combat fatal diseases, today announced that CEO Noreen McGurrin Griffin and CMO Dr. Ronald Herberman will be speaking at the 6th Annual OneMedForum taking place in San Francisco, CA, on January 7-9, 2013. Ms. Griffin and Dr. Herberman will provide an update on the company’s business activities for 2012 as well as plans for 2013. TNI BioTech’s presentation is scheduled for Wednesday, January 9, 2013, at 11:20 am PST. For more information on TNI BioTech, visit www.TNIBioTech.com Let us hear your thoughts below:

ThursdayJan 03, 2013 7:34 am

Ashley Keller Joins Vringo, Inc. (VRNG) Board of Directors

Yesterday, mobile technologies and intellectual properties developer Vringo announced that Mr. Ashley Keller has joined the company’s Board of Directors. He will serve on the Audit and Compensation Committees of the Board of Directors. Mr. Keller is currently a special situations analyst at Alyeska Investment Group, a multi-strategy hedge fund based in Chicago, where he focuses on investments in companies involved in complex and high-stakes commercial litigation and regulatory matters. “I am honored to join the Vringo board of directors. Thanks to the execution of the company’s exceptional management team, Vringo is an emerging leader in innovating, licensing and protecting…

ThursdayJan 03, 2013 7:33 am

Cardium Therapeutics, Inc. (CXM) to Increase Excellagen Clinical Adoption by U.S. Government Medical Providers via New Distribution Agreement

Today before the opening bell, Cardium Therapeutics announced it has entered a distribution agreement with Academy Medical, LLC to market, sell, and distribute Excellagen to U.S. government medical providers, including the Veterans Administration (VA) healthcare system and military hospitals. An FDA-cleared gel, Excellagen is used to support advanced wound care in a broad range of dermal wounds. Academy Medical’s will initially focus on providing education and training on the use of Excellagen in the treatment of traumatic wounds, non-healing venous, pressure and diabetic ulcers, limb salvage, and post-Mohs skin cancer surgery, while supporting distribution within its growing customer base of…

ThursdayJan 03, 2013 7:33 am

International Stem Cell Corp. (ISCO) Scheduled to Present at the Biotech Showcase 2013 Conference

International Stem Cell Corp., a biotechnology company specializing in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products, today announced that Executive Vice President, Dr. Simon Craw, will be presenting at the Biotech Showcase™ 2013 conference early next week. The event is being held in San Francisco at the Parc 55 Wyndham Union Square Hotel. Presentation Details Date: Monday, January 7, 2013 Time: 9:30 pm PST Location: Parc 55 Wyndham Union Square Hotel, San Francisco, CA Room: Room Mission II – Track C Those who wish to attend the…

WednesdayJan 02, 2013 2:57 pm

Innovation Marketing Names AVT, Inc. (AVTC) a Leading Force

Innovation Marketing formally recognized AVT as a leading force behind one of the three biggest trends that Innovation has forecast for 2013 in a report titled “3 Vital Trends of 2013.” ATV is focused on developing automated and self-service retail systems, such as the LCD iVend Stores, AR Walls, and other self-service kiosks and high-end vending machines. ATV claims that their automated retail solutions drive traffic, increases sales, improves security, and lower overhead. In the report, Innovation states that evolving technology and component design will see retail moving more steadily towards automation. Driving these efforts will be attention-getting features such…

WednesdayJan 02, 2013 2:56 pm

Soligenix, Inc. (SNGX) Receives Orphan Drug Designation for OrbeShield™

The U.S. FDA’s Office of Orphan Products Development has granted orphan drug designation to Soligenix Inc.’s OrbeShield™ (oral BDP) as a measure to prevent death following a potentially lethal dose of total body irradiation during or after a radiation disaster. Oral BDP, a highly potent, topically active corticosteroid, is the active ingredient in OrbeShield™, which is currently being developed for the treatment of gastrointestinal acute radiation syndrome (GI ARS), a leading cause of mortality following high doses of total body irradiation (TBI). Orphan drug designation provides a seven-year term of market exclusivity for oral BDP upon final FDA approval, and…

WednesdayJan 02, 2013 2:55 pm

Dejour Energy Inc. (DEJ) Secures $6.5M Deal with Local Drilling Fund to Develop Massive Potential at Kokopelli Field in Colorado

Dejour Energy, the domestic oil and gas developer focused on their sizeable holdings in the Rocky Mountains (some 130k net acres across multiple projects in the Piceance, Uinta, and Paradox Basins of Utah and Colorado), as well as their acreage up in the Alberta/BC region (11k net acres in the Peace River Arch projects), reported today that the company has entered into an agreement valued at $6.5M with a private, Denver-based drilling fund to help complete the first well, in addition to the drilling/completion of three more wells by early 2013, at their 2.2k-acre Kokopelli field development project in northwestern…

WednesdayJan 02, 2013 2:55 pm

GlobalWise Investments, Inc. (GWIV) and Cloud Disaster Recovery

It has been estimated that the global cloud computing industry could be worth nearly a quarter of a trillion dollars by the end of the current decade, with cloud storage playing a major role in that growth. The overall benefits of cloud storage and processing are increasingly well known: Cloud computing reduces up-front investment in hardware and software; it provides flexible levels of storage and service as your business requirements change; it offers tremendous flexibility for data access, especially important for companies with scattered facilities and mobile employees. However, for small businesses that have yet to tap into the cloud,…

Site Search

Company Search